Catalyst Pharmaceuticals (CPRX) Liabilities and Shareholders Equity (2010 - 2026)

Catalyst Pharmaceuticals' Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $1.1 billion for Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 26.27% year-over-year to $1.1 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.3 billion (up 32.0% YoY) and the FY2025 annual result came in at $1.1 billion, up 29.66% from the prior year.
• Liabilities and Shareholders Equity was $1.1 billion for Q1 2026 at Catalyst Pharmaceuticals, up from $1.1 billion in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $1.1 billion in Q1 2026 and bottomed at $247.0 million in Q1 2022.
• A 5-year average of $654.0 million and a median of $646.7 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity climbed 24.04% — and 2024, when it soared 86.83%.
• Catalyst Pharmaceuticals' Liabilities and Shareholders Equity stood at $375.6 million in 2022, then rose by 25.15% to $470.1 million in 2023, then surged by 81.11% to $851.4 million in 2024, then climbed by 29.66% to $1.1 billion in 2025, then grew by 3.95% to $1.1 billion in 2026.
• Business Quant data shows CPRX's Liabilities and Shareholders Equity at $1.1 billion in Q1 2026, $1.1 billion in Q4 2025, and $1.1 billion in Q3 2025.